Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy
International Journal of Cancer, 05/04/2012
Terpos E et al. – The results suggest that patients with active myeloma have elevated circulating sclerostin, which correlated with advanced disease features including severe bone disease. The study indicates sclerostin as a possible target for the development of novel therapies to enhance osteoblast function in myeloma.